Search results for "ASPIRIN"

showing 10 items of 146 documents

Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease

2013

Background Nasal polyposis frequently occurs within the clinical picture of aspirin-exacerbated respiratory disease (AERD). A derailed arachidonic acid metabolism is regarded to be part of the pathophysiology of AERD, and aspirin desensitization is the only causal therapeutic option, so far. The optimal maintenance dose of aspirin desensitization to prevent nasal polyp recurrence on the one hand and to minimize aspirin-related side-effects, on the other hand, is still a matter of debate. The aim of this trial was to investigate the efficacy and safety of a low-dose aspirin desensitization protocol. Methods After sinus surgery, 70 individuals with AERD were randomly allocated to a prospectiv…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologylaw.inventionDrug HypersensitivityQuality of lifeRandomized controlled trialRecurrencelawSurveys and QuestionnairesInternal medicineRespiratory HypersensitivitymedicineHumansImmunology and AllergyDesensitization (medicine)AspirinAspirinMaintenance dosebusiness.industryRespiratory diseaseMiddle Agedmedicine.diseasePathophysiologyClinical trialTreatment OutcomeDesensitization ImmunologicAnesthesiaQuality of LifeFemalebusinessFollow-Up Studiesmedicine.drugAllergy
researchProduct

Joint effect of blood pressure and C-reactive protein and the risk of sudden cardiac death : a prospective cohort study

2020

Background Both blood pressure and C-reactive protein (CRP) are each independently related to mortality risk. However, the combined effect of systolic blood pressure (SBP) and CRP on sudden cardiac death (SCD) risk has not been studied. Patients and methods We studied the joint impact of SBP and CRP and the risk of SCD in the Kuopio Ischemic Heart Disease prospective cohort study of 1953 men aged 42–61 years with no history of ischemic heart disease. Baseline investigations were conducted between March 1984 and December 1989. SBP and CRP were measured. SBP was divided based on median values to low and high (median cutoffs 132 mmHg) and CRP as low and high (median cut-off 1.30 mg/L). Hazard …

AdultMalemedicine.medical_specialtysystolic blood pressuremenBlood PressurebiomarkkeritType 2 diabetes030204 cardiovascular system & hematologysudden cardiac deathSudden cardiac deathC-reactive proteinCohort Studies03 medical and health sciences0302 clinical medicineRisk Factorsc-reaktiivinen proteiiniInternal medicinemedicinekohonnut verenpaineHumansProspective Studies030212 general & internal medicineProspective cohort studyAspirinbiologybusiness.industryHazard ratioC-reactive proteinriskitekijätMiddle Agedmedicine.diseaseverenpaineC-Reactive ProteinDeath Sudden CardiacBlood pressureDiabetes Mellitus Type 2sydäninfarktibiology.proteinCardiologysydän- ja verisuonitauditmiehetCardiology and Cardiovascular MedicinebusinessCohort studymedicine.drug
researchProduct

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss…

2003

Objective To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL). Methods We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the th…

Adultmedicine.medical_specialtyAbortion HabitualAdolescentmedicine.drug_classImmunologyLow molecular weight heparinGastroenterologyRoute of administrationRandom AllocationRheumatologyAntiphospholipid syndromePregnancyInternal medicinemedicineImmunology and AllergyHumansPharmacology (medical)PregnancyLupus anticoagulantAspirinAspirinbusiness.industryAnticoagulantPregnancy OutcomeAnticoagulantsImmunoglobulins IntravenousHeparinHeparin Low-Molecular-Weightmedicine.diseaseAntiphospholipid SyndromeSurgeryPregnancy ComplicationsTreatment OutcomeDrug Therapy CombinationFemalebusinessmedicine.drugArthritis and rheumatism
researchProduct

Antiphospholipid syndrome in obstetrics.

2003

Antiphospholipid syndrome (APLS) in pregnancy is characterized by the presence of autoantibodies in association with recurrent fetal loss and severe complications such as preeclampsia, fetal growth retardation, or placental insufficiency. The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and recently anti-beta-2-glycoprotein 1 antibodies. At present, standardization does not exist and a definitive association between specific clinical manifestation and antibody level is not yet known. Experimental data gave evidence that passive transfer of antiphospholipid antibodies result in clinical manifestation of APLS, that is, fetal loss and thromb…

Adultmedicine.medical_specialtyAbortion HabitualPlacental insufficiency030204 cardiovascular system & hematologyGastroenterologyPreeclampsia03 medical and health sciences0302 clinical medicinePre-Eclampsiaimmune system diseasesAntiphospholipid syndromePregnancyInternal medicinemedicinePrevalenceHumansThrombophiliaAnnexin A5030203 arthritis & rheumatologyLupus anticoagulantAspirinPregnancyFetal Growth RetardationAspirinbusiness.industryHeparinStandard treatmentInfant NewbornAnticoagulantsImmunoglobulins IntravenousHematologyGeneral MedicineHeparinmedicine.diseaseAntiphospholipid SyndromePlacental InsufficiencyThrombocytopeniaAbortion SpontaneousPregnancy ComplicationsAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyPrednisoneFemalebusinessImmunity Maternally-AcquiredImmunosuppressive Agentsmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study

2021

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a clinical entity with specific features that impacts significantly on patient quality of life (QoL). CRSwNP is often associated with asthma and is difficult to control and manage despite pharmacological and/or surgical treatment. Omalizumab, a monoclonal anti-IgE antibody, has emerged as a putative therapeutic option. Objective To evaluate the effects of omalizumab on nasal polyp (NP) size and QoL assessed by Sino-Nasal Outcome Test-22 (SNOT-22) in patients with recalcitrant CRSwNP and mild asthma. Methods A multicenter retrospective analysis of patient data from the Community of Valencia (Spain) was performed. Adult patients …

Adultmedicine.medical_specialtyMild asthmaOmalizumabOmalizumabaspirin-exacerbated respiratory diseasechronic rhinosinusitis with nasal polypsImmunoglobulin E03 medical and health sciencesNasal Polyps0302 clinical medicineQuality of lifeSNOT-22Internal medicinemedicineHumansImmunology and AllergyNasal polypsIn patient030223 otorhinolaryngologyRetrospective StudiesRhinitisnasal polypsbiologybusiness.industrytotal nasal endoscopic polyp scoreRetrospective cohort studyGeneral Medicinemedicine.diseaseAsthmaTreatment Outcomequality of lifetissue eosinophilia030228 respiratory systemOtorhinolaryngologyIgE SNOT-22 aspirin-exacerbated respiratory disease chronic rhinosinusitis with nasal polyps mild asthma nasal polyps omalizumab quality of life tissue eosinophilia total nasal endoscopic polyp scoreChronic DiseaseQuality of Lifebiology.proteinomalizumabAspirin exacerbated respiratory diseaseIgEbusinessmild asthmamedicine.drugAmerican Journal of Rhinology & Allergy
researchProduct

In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition.

2002

Understanding the formation of extracellular amyloid neurofibrillar bundles/senile plaques and their role in the development of Alzheimer's disease is of considerable interest to neuroscientists and clinicians. Major components of the extracellular neurofibrillar bundles are polymerized amyloid beta (Abeta) peptides (1-40), (1-42) and (1-43), derived in vivo from the soluble amyloid precursor protein (sAPP) by proteolytic (beta- and gamma-secretase) cleavage. The Abeta(1-42) peptide is widely considered to be of greatest significance in relation to the pathogenesis of Alzheimer's disease. A well-defined ultrastructural characteristic within Alzheimer dense plaques is the presence of helical…

AmyloidAmyloid betaGeneral Physics and AstronomyPeptideFibrilStructural BiologyAlzheimer DiseaseAmyloid precursor proteinAnimalsHumansGeneral Materials ScienceSenile plaqueschemistry.chemical_classificationAmyloid beta-PeptidesbiologyAspirinChemistryP3 peptideFibrillogenesisCell BiologyRatsSphingomyelinsMicroscopy ElectronCholesterolBiochemistrybiology.proteinlipids (amino acids peptides and proteins)PeptidesDimerizationCopperMicron (Oxford, England : 1993)
researchProduct

Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

2015

Abstract The objective of this paper is to apply a previously developed semi-physiologic pharmacokinetic model implemented in NONMEM to simulate bioequivalence trials (BE) of acetyl salicylic acid (ASA) in order to validate the model performance against ASA human experimental data. ASA is a drug with first-pass hepatic and intestinal metabolism following Michaelis–Menten kinetics that leads to the formation of two main metabolites in two generations (first and second generation metabolites). The first aim was to adapt the semi-physiological model for ASA in NOMMEN using ASA pharmacokinetic parameters from literature, showing its sequential metabolism. The second aim was to validate this mod…

AnalyteChemistry PharmaceuticalMetaboliteCmaxPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalBiomarkers PharmacologicalFirst pass effectchemistry.chemical_compoundPharmacokineticsIn vivoHumansMedicineComputer SimulationTissue DistributionBiotransformationChromatographyAspirinDose-Response Relationship Drugbusiness.industryHippuratesAnti-Inflammatory Agents Non-SteroidalNONMEMDrug LiberationTherapeutic EquivalencychemistryPharmacology ClinicalSalicylic AcidbusinessAlgorithmsSoftwareEuropean Journal of Pharmaceutical Sciences
researchProduct

Heat Stress Induces Extended Plateau of Hsp70 Accumulation - A Possible Cytoprotection Mechanism in Hepatic Cells

2015

The relevance of heat preconditioning resides in its ability to protect cells from different kinds of injury by induction of heat shock proteins, a process in which the intensity of heat stress (HS) and duration of subsequent recovery are vital. This study evaluates the effects of moderate HS (45 min/43°C) and the time-dependent changes during recovery period of HSP70, Bcl-2 and p53 gene and protein expression in HepG2 cells. We also evaluated the effects of 0.4 mM aspirin (ASA) as a potential pharmacological co-inducer of HSP, both alone and in a combination with HS (ASA + HS). HS alone and ASA + HS caused a major up-regulation of HSP70 mRNA in the first 2 h, while HSP70 protein increased …

AspirinCellCell BiologyBiologyBiochemistryCytoprotectionLiver regenerationHsp70Cell biologymedicine.anatomical_structureBiochemistryHeat shock proteinGene expressionHepatic stellate cellmedicineMolecular Biologymedicine.drugJournal of Cellular Biochemistry
researchProduct

520 EFFECT OF CYCLOOXYGENASE-1 POLYMORPHISMS ON URINARY 11-DEHYDROTHROMBOXANE B2 LEVELS IN PATIENTS UNDERGOING STENT IMPLANTATION PRETREATED WITH ASP…

2011

Aspirinmedicine.medical_specialtybiologybusiness.industryUrinary systemUrologyGeneral MedicineAnesthesiaInternal Medicinemedicinebiology.proteinStent implantationIn patientCyclooxygenaseCardiology and Cardiovascular Medicinebusiness11-dehydrothromboxane B2medicine.drugAtherosclerosis Supplements
researchProduct

Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic thera…

1999

The benefit of primary angioplasty in patients with acute myocardial infarction (AMI) and contraindications for thrombolysis compared to a conservative regimen is still unclear. Out of 5,869 patients with AMI registered by the MITRA trial, 337 (5.7%) patients had at least one strong contraindication for thrombolytic therapy. Out of these 337 patients 46 (13.6%) were treated with primary angioplasty and 276 (86.4%) were treated conservatively. Patients treated conservatively were older (70 years vs. 60 years; P = 0.001), had a higher rate of a history with chronic heart failure (14.8% vs. 4.4%; P = 0.053), a higher heart rate at admission (86 beats/min vs. 74 beats/min; P = 0.001), and a hig…

Aspirinmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGeneral MedicineThrombolysismedicine.diseaseRegimenInternal medicineDiabetes mellitusHeart failureHeart ratemedicineCardiologyRadiology Nuclear Medicine and imagingMyocardial infarctionCardiology and Cardiovascular MedicinebusinessContraindicationmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct